Free Trial
→ New Rule Hits in July — The Smart Money Already Moved (From American Alternative) (Ad)
NASDAQ:SRRK

Scholar Rock Q4 2023 Earnings Report

Scholar Rock logo
$32.45 -0.87 (-2.61%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$32.73 +0.28 (+0.88%)
As of 04:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings HistoryForecast

Scholar Rock EPS Results

Actual EPS
-$0.50
Consensus EPS
-$0.49
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

Scholar Rock Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Scholar Rock Announcement Details

Quarter
Q4 2023
Date
3/19/2024
Time
N/A
Conference Call Date
Tuesday, March 19, 2024
Conference Call Time
8:00AM ET

Upcoming Earnings

Scholar Rock's Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 8:15 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Scholar Rock's Q4 2023 Press ReleasePress Release
(8-K)
Scholar Rock's Q4 2023 Annual reportAnnual report
(10-K)

Scholar Rock Earnings Headlines

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 13 at 4:15 PM | businesswire.com
Scholar Rock (NASDAQ:SRRK) Upgraded at Lifesci Capital
June 6, 2025 | americanbankingnews.com
New Rule Hits in July — The Smart Money Already Moved
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
June 16, 2025 | American Alternative (Ad)
Scholar Rock Appoints Rebecca McLeod Chief Brand Officer and U.S. General Manager
June 2, 2025 | uk.finance.yahoo.com
Scholar Rock to Present at the Jefferies Global Healthcare Conference
May 28, 2025 | businesswire.com
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 16, 2025 | businesswire.com
See More Scholar Rock Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Scholar Rock? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scholar Rock and other key companies, straight to your email.

About Scholar Rock

Scholar Rock (NASDAQ:SRRK), a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

View Scholar Rock Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles